Cargando…
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
BACKGROUND: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable HCC were randomized 1:...
Autores principales: | Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Nagamatsu, Hiroaki, Ishii, Hiroshi, Yokosuka, Osamu, Torimura, Takuji, Morimoto, Manabu, Ikeda, Kenji, Kumada, Hiromitsu, Sato, Tosiya, Kawai, Ikuko, Yamashita, Toru, Horio, Hiroshi, Okusaka, Takuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846877/ https://www.ncbi.nlm.nih.gov/pubmed/28766016 http://dx.doi.org/10.1007/s00535-017-1374-6 |
Ejemplares similares
-
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019) -
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016) -
Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort
por: Okusaka, Takuji, et al.
Publicado: (2023) -
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
por: Okita, Kiwamu, et al.
Publicado: (2014) -
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
por: Okusaka, Takuji, et al.
Publicado: (2021)